Lexaria Bioscience Corp. Announces Closing of $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

 Kelowna, British Columbia – December 16, 2025 – TheNewswire - Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of an aggregate of 2,661,600 shares of its common stock, par value $0.001 per share, at a purchase price of $1.315 per share. In addition, in a concurrent private placement, the Company issued unregiste ...